These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 20460491)

  • 1. FTY720 shows promising in vitro and in vivo preclinical activity by downmodulating Cyclin D1 and phospho-Akt in mantle cell lymphoma.
    Liu Q; Alinari L; Chen CS; Yan F; Dalton JT; Lapalombella R; Zhang X; Mani R; Lin T; Byrd JC; Baiocchi RA; Muthusamy N
    Clin Cancer Res; 2010 Jun; 16(12):3182-92. PubMed ID: 20460491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720 increases CD74 expression and sensitizes mantle cell lymphoma cells to milatuzumab-mediated cell death.
    Alinari L; Mahoney E; Patton J; Zhang X; Huynh L; Earl CT; Mani R; Mao Y; Yu B; Quinion C; Towns WH; Chen CS; Goldenberg DM; Blum KA; Byrd JC; Muthusamy N; Praetorius-Ibba M; Baiocchi RA
    Blood; 2011 Dec; 118(26):6893-903. PubMed ID: 22042694
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines.
    Shirsath NP; Manohar SM; Joshi KS
    Mol Cancer; 2012 Oct; 11():77. PubMed ID: 23075291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation.
    Lee TK; Man K; Ho JW; Sun CK; Ng KT; Wang XH; Wong YC; Ng IO; Xu R; Fan ST
    Carcinogenesis; 2004 Dec; 25(12):2397-405. PubMed ID: 15297371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FTY720-induced blockage of autophagy enhances anticancer efficacy of milatuzumab in mantle cell lymphoma: is FTY720 the next autophagy-blocking agent in lymphoma treatment?
    Alinari L; Baiocchi RA; Praetorius-Ibba M
    Autophagy; 2012 Mar; 8(3):416-7. PubMed ID: 22377620
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma.
    Liu Q; Zhao X; Frissora F; Ma Y; Santhanam R; Jarjoura D; Lehman A; Perrotti D; Chen CS; Dalton JT; Muthusamy N; Byrd JC
    Blood; 2008 Jan; 111(1):275-84. PubMed ID: 17761520
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FTY720 induces autophagy-related apoptosis and necroptosis in human glioblastoma cells.
    Zhang L; Wang H; Ding K; Xu J
    Toxicol Lett; 2015 Jul; 236(1):43-59. PubMed ID: 25939952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN- and p53-mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice.
    Zheng T; Meng X; Wang J; Chen X; Yin D; Liang Y; Song X; Pan S; Jiang H; Liu L
    J Cell Biochem; 2010 Sep; 111(1):218-28. PubMed ID: 20506484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system.
    Pereira FV; Arruda DC; Figueiredo CR; Massaoka MH; Matsuo AL; Bueno V; Rodrigues EG
    Clinics (Sao Paulo); 2013 Jul; 68(7):1018-27. PubMed ID: 23917669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling.
    Lu Z; Wang J; Zheng T; Liang Y; Yin D; Song R; Pei T; Pan S; Jiang H; Liu L
    BMC Cancer; 2014 Oct; 14():783. PubMed ID: 25344679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinoma.
    Omar HA; Chou CC; Berman-Booty LD; Ma Y; Hung JH; Wang D; Kogure T; Patel T; Terracciano L; Muthusamy N; Byrd JC; Kulp SK; Chen CS
    Hepatology; 2011 Jun; 53(6):1943-58. PubMed ID: 21391227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ROR1-targeted delivery of OSU-2S, a nonimmunosuppressive FTY720 derivative, exerts potent cytotoxicity in mantle-cell lymphoma in vitro and in vivo.
    Mani R; Chiang CL; Frissora FW; Yan R; Mo X; Baskar S; Rader C; Klisovic R; Phelps MA; Chen CS; Lee RJ; Byrd JC; Baiocchi R; Lee LJ; Muthusamy N
    Exp Hematol; 2015 Sep; 43(9):770-4.e2. PubMed ID: 25937048
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclin D1-CDK4 activity drives sensitivity to bortezomib in mantle cell lymphoma by blocking autophagy-mediated proteolysis of NOXA.
    Heine S; Kleih M; Giménez N; Böpple K; Ott G; Colomer D; Aulitzky WE; van der Kuip H; Silkenstedt E
    J Hematol Oncol; 2018 Sep; 11(1):112. PubMed ID: 30180865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cyclin-D1 interaction with BAX underlies its oncogenic role and potential as a therapeutic target in mantle cell lymphoma.
    Beltran E; Fresquet V; Martinez-Useros J; Richter-Larrea JA; Sagardoy A; Sesma I; Almada LL; Montes-Moreno S; Siebert R; Gesk S; Calasanz MJ; Malumbres R; Rieger M; Prosper F; Lossos IS; Piris MA; Fernandez-Zapico ME; Martinez-Climent JA
    Proc Natl Acad Sci U S A; 2011 Jul; 108(30):12461-6. PubMed ID: 21746927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Deferasirox induces cyclin D1 degradation and apoptosis in mantle cell lymphoma in a reactive oxygen species- and GSK3β-dependent mechanism.
    Samara A; Shapira S; Lubin I; Shpilberg O; Avigad S; Granot G; Raanani P
    Br J Haematol; 2021 Feb; 192(4):747-760. PubMed ID: 33521925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia.
    Liao A; Broeg K; Fox T; Tan SF; Watters R; Shah MV; Zhang LQ; Li Y; Ryland L; Yang J; Aliaga C; Dewey A; Rogers A; Loughran K; Hirsch L; Jarbadan NR; Baab KT; Liao J; Wang HG; Kester M; Desai D; Amin S; Loughran TP; Liu X
    Blood; 2011 Sep; 118(10):2793-800. PubMed ID: 21768294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
    Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
    Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumoral activity of lenalidomide in in vitro and in vivo models of mantle cell lymphoma involves the destabilization of cyclin D1/p27KIP1 complexes.
    Moros A; Bustany S; Cahu J; Saborit-Villarroya I; Martínez A; Colomer D; Sola B; Roué G
    Clin Cancer Res; 2014 Jan; 20(2):393-403. PubMed ID: 24178620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticarcinogenic effect of FTY720 in human prostate carcinoma DU145 cells: modulation of mitogenic signaling, FAK, cell-cycle entry and apoptosis.
    Permpongkosol S; Wang JD; Takahara S; Matsumiya K; Nonomura N; Nishimura K; Tsujimura A; Kongkanand A; Okuyama A
    Int J Cancer; 2002 Mar; 98(2):167-72. PubMed ID: 11857403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
    Wallington-Beddoe CT; Don AS; Hewson J; Qiao Q; Papa RA; Lock RB; Bradstock KF; Bendall LJ
    PLoS One; 2012; 7(5):e36429. PubMed ID: 22570713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.